New collaboration delivers cashless services, as well as access to expedited appointments for outpatient cancer treatment services and independent cancer medical consultation, ens ...
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay ...